At a glance
ClinicalIndex Comparison RecordN/ACompleted· 295 enrolled
Drug / intervention
Telmisartan or Telmisartan and Hydrochlorthiazidedrug
Likely dose
Telmisartan or Telmisartan and Hydrochlorthiazide 80mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg; 80/25 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients
In Brief
An observational study evaluating Telmisartan or Telmisartan and Hydrochlorthiazide for Hypertension. Completed, enrolled 295 participants across 49 sites.
Detailed Summary
The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on blood pressure and its ability to reduce different indicated cardiovascular risk scores. The study will also evaluate the current antihypertensive treatment pattern in the daily practice among the patient population at increased cardiovascular risk.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesRomania
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
First PostedApr 2010
Primary CompletionJan 2011
TodayJul 2026
First PostedApr 22, 2010
Enrollment StartApr 1, 2010
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 16.2 years ago
Interventions
Telmisartan or Telmisartan and Hydrochlorthiazidedrug
Telmisartan 80mg +/- Hydrochlorthiazide 12.5mg or 25mg